Eli Lilly is expanding its offerings of its hit weight-loss drug Zepbound for people who want to pay cash instead of using ...

Eli Lilly stock surges past $840, outperforming the S&P 500. Click here to learn why LLY stock is still undervalued and why ...

Eli Lilly and Company (NYSE: LLY) announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, ...

In this article, we will take a look into Eli Lilly and Co's (NYSE:LLY) DCF analysis, a reliable and data-driven approach to ...

Eli Lilly's stock offers high growth potential, driven by GLP-1 therapies and strong R&D efforts. Read why LLY stock is ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...

We recently compiled a list of the 20 High Growth Mega Cap Stocks You Can Buy And Hold For Next 5 Years. In this article, we ...

Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel ...

Joe Nadglowski, president and CEO of the Obesity Action Coalition (OAC), appreciated Lilly's efforts to make obesity ...

Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses ...